Management of Dysplastic Barrett's Esophagus and Early Esophageal Adenocarcinoma
Gastroenterology clinics of North America · 2022 Sep
Abstract
While patients with Barrett's esophagus without dysplasia may benefit from endoscopic surveillance, those with low-grade dysplasia may be managed with either endoscopic surveillance or endoscopic eradication. Patients with Barrett's esophagus with high-grade dysplasia and/or intramucosal adenocarcinoma will generally require endoscopic eradication therapy. The management of Barrett's esophagus with dysplasia and early esophageal adenocarcinoma is predominantly endoscopic, with multiple effective methods available for the resection of raised neoplasia and ablation of flat neoplasia. High-dose proton-pump inhibitor therapy is advised during the treatment of Barrett's esophagus with dysplasia and early esophageal adenocarcinoma. After the endoscopic eradication of Barrett's esophagus and associated neoplasia, surveillance is required for the diagnosis and retreatment of recurrence or progression.
Neurotransmitters
None linked yet.
Related
None linked yet.
Ratings (0): Breadth — · Depth — · Enjoyment — · Usefulness —
Community
Log in to rate and share your notes.
No contributions yet.